Yüklüyor......

Transfusion-dependent anaemia treatment using continuous erythropoietin receptor activator (epoetin β pegol) and roxadustat after darbepoetin treatment failure in low-risk myelodysplastic syndrome: a case report

Treatment of anaemia and reduction of transfusion are major therapeutic goals in patients with low-risk myelodysplastic syndrome (MDS). Although erythropoiesis-stimulating agents (ESAs) are widely used to reduce transfusion requirement, ESAs lose effectiveness within 12 months. We report a 65-year-o...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Oxf Med Case Reports
Asıl Yazarlar: Ikenoue, Tatsuyoshi, Furumatsu, Yoshiyuki, Kitamura, Tetsuya
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Oxford University Press 2021
Konular:
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC8143669/
https://ncbi.nlm.nih.gov/pubmed/34055362
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/omcr/omab026
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!